Mary (Beth) Goad, DVM, PhD, ACVP, ACLAM, ABT

Preclinical Development, Toxicology

Mary (Beth)  Goad has been active in drug development from discovery to post approval Phase 4 studies and has worked with small molecules, vaccines, proteins (including growth factors and antibodies) oligonucleotudes, stem cells, and a wide variety of devices. Dr. Goad is a DVM (from LSU) with a PhD in Comparative and Experimental Medicine (from the University of Tennessee); she is board-certified in veterinary pathology, laboratory animal medicine, and toxicology.  She has worked at MIT, LSU, Tufts Cummingss School of Veterinary Medicine academic laboratories. She became experienced as a toxicologic pathologist and study director at EG&G Mason (later CRL) and  Arthur D Little. Dr. Goad was responsible for the preclinical efficacy and toxicology for devices at ETEX. As director of Investigative Pathology at Wyeth Pharmaceuticals, Beth was in charge of providing support for early discovery phase compounds as well as support for toxicology issues for all the programs (oncology, vaccines, infectious diseases, women’s health and bone, and cardiovascular/metabolic disorders). She was responsible for the strategy for individual drug programs including but not limited to BMP-2.  At Stryker, Beth was responsible for the toxicology program for the several indications for BMP-7. She has worked as a consultant for several biotechnology companies in the Boston area in fields ranging from devices to small molecules to proteins and vaccines.